Rai, R.; Gong Essel, K.; Mangiaracina Benbrook, D.; Garland, J.; Daniel Zhao, Y.; Chandra, V.
Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer. Cancers 2020, 12, 1273.
https://doi.org/10.3390/cancers12051273
AMA Style
Rai R, Gong Essel K, Mangiaracina Benbrook D, Garland J, Daniel Zhao Y, Chandra V.
Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer. Cancers. 2020; 12(5):1273.
https://doi.org/10.3390/cancers12051273
Chicago/Turabian Style
Rai, Rajani, Kathleen Gong Essel, Doris Mangiaracina Benbrook, Justin Garland, Yan Daniel Zhao, and Vishal Chandra.
2020. "Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer" Cancers 12, no. 5: 1273.
https://doi.org/10.3390/cancers12051273
APA Style
Rai, R., Gong Essel, K., Mangiaracina Benbrook, D., Garland, J., Daniel Zhao, Y., & Chandra, V.
(2020). Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer. Cancers, 12(5), 1273.
https://doi.org/10.3390/cancers12051273